We are Merus

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Management Team

Ton Logtenberg, Ph.D

Chief Executive Officer

Mark Throsby, Ph.D

EVP & Chief Scientific Officer

L. Andres Sirulnik, M.D. Ph.D

EVP & Chief Medical Officer

Lex Bakker, Ph.D

SVP & Chief Development Officer

John de Kruif, Ph.D

SVP & Chief Technology Officer

Hui Liu, Ph.D

EVP, Chief Business Officer & Head of Merus U.S.

Peter B. Silverman, J.D.

EVP & General Counsel
Ton Logtenberg, Ph.D
Chief Executive Officer

Ton Logtenberg, Ph.D. has served as our Chief Executive Officer and an executive board member since co-founding our company in June 2003.

Prior to joining Merus, Dr. Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003.

Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of Utrecht Science Park since November 2014. Dr. Logtenberg holds a Ph.D. in medical biology from Utrecht University.

Mark Throsby, Ph.D
EVP & Chief Scientific Officer

Mark Throsby, Ph.D. has served as our Chief Scientific Officer since January 2013 and previously served as our Chief Operating Officer from October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, pre-clinical research and translational research, business development support, external collaborations and partnerships management.

Before joining Merus, from October 2000 to October 2008, he served as a senior scientist and then as director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr. Throsby holds a Ph.D. in immunology from Monash University.

L. Andres Sirulnik, M.D. Ph.D
EVP & Chief Medical Officer

Andres Sirulnik, M.D., Ph.D. has served as our Chief Medical Officer since October 2016. His responsibilities include clinical strategy and development.

Prior to joining Merus, Dr. Sirulnik was at Novartis Pharmaceuticals from 2008 to 2016, most recently serving as Vice President – Senior Global Clinical Program Head and Research Physician in Oncology Clinical Development. From 2003 to 2008, Dr. Sirulnik was an attending physician in the leukemia program at Dana Farber Cancer Institute and Instructor in Medicine at Harvard Medical School where he focused his research and clinical work in rare hematologic malignancies.

Dr. Sirulnik received his medical degree from the University of Buenos Aires, Argentina, and his Ph.D. in medicine and molecular biology at the University of Cambridge, England.

Lex Bakker, Ph.D
SVP & Chief Development Officer

Lex Bakker, Ph.D. has served as our Chief Development Officer since October 2010. His responsibilities include strategic scientific leadership, management of preclinical and clinical development and manufacturing, business development support, external collaboration and partnership management.

Prior to joining Merus, Dr. Bakker directed preclinical and clinical development at Crucell N.V., a biotechnology company. Mr. Bakker holds a Ph.D in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute.

John de Kruif, Ph.D
SVP & Chief Technology Officer

John de Kruif, Ph.D. has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody engineering, external collaborations, partnerships management and operational activities.

Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a PhD in Antibody Engineering from Utrecht University.

Hui Liu, Ph.D
EVP, Chief Business Officer & Head of Merus U.S.

Hui Liu, Ph.D. has served as our Chief Business Officer since December 2015. His responsibilities include all aspects of business development, including in- and out- licensing, acquisitions and alliance management. Prior to joining Merus, Dr. Liu served as Vice President and Global Head, Business Development & Licensing, Oncology at Novartis AG, a pharmaceutical company, from 2013 to 2015, and as Vice President and Global Head, Business Development & Licensing, Vaccines & Diagnostics, from 2009 to 2012.

Prior to Novartis, Dr. Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to 2009 and at Pfizer, Inc. and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University.

Peter B. Silverman, J.D.
EVP & General Counsel

Peter B. Silverman, J.D. has served as our General Counsel since February 2018 and our Chief Intellectual Property Officer since February 2017. His responsibilities include management of the company’s legal strategy and overseeing all aspects of the company’s legal operations.

Prior to joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters. Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.

Board of Directors

Russell Greig

Chairman

Ton Logtenberg, Ph.D

Chief Executive Officer

Mark Iwicki

Member

Len Kanavy

Member

John de Koning, Ph.D

Member

Greg Perry, C.P.A.

Member

Anand Mehra, M.D.

Member

Anne Noordzij

Secretary
Russell Greig
Chairman

Dr. Russell Greig is Chairman of our board of directors and has been a member of the board since July 2018. With more than 35 years’ experience in the pharmaceutical and biotechnology industry, Dr. Greig has extensive expertise in research and development, business development and commercial operations. Dr. Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group.

Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008, as well as serving on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as the Chair of AM Pharma and MedEye Solutions (Netherlands), eTheRNA (Belgium), Horama (France) and Sanifit (Spain/US).

He was previously Chair of Ablynx (Belgium) prior to its acquisition by Sanofi in 2018, and as a NED of Tigenix (Belgium/Spain) prior to its pending acquisition by Takeda in 2018. Dr Greig was also Chair of Isconova (Sweden) acquired by Novavax (United States), Novagali (France) acquired by Santen (Japan), and Syntaxin (United Kingdom) acquired by Ipsen (France). He has served as a venture partner at Kurma Partners (France). Finally, Dr. Greig was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.

Ton Logtenberg, Ph.D
Chief Executive Officer

Ton Logtenberg has served as our Chief Executive Officer and as board member since co-founding our Company in June 2003.

Prior to joining Merus, Dr. Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003.

Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of Utrecht Science Park since November 2014. Dr. Logtenberg holds a Ph.D. in medical biology from Utrecht University.

Mark Iwicki
Member

Mark Iwicki has been a member of the board since June 2015. Mr. Iwicki also serves as the chief executive officer and chairman of the board of directors of Kala Pharmaceuticals, Inc. and as a member of the boards of directors of Aimmune Therapeutics, Inc., Nimbus Therapeutics, TARIS Biomedical and Oxeia Biopharmaceuticals.

In addition, Mr. Iwicki has served on the board of the Wellesley Youth Hockey Association. Mr. Iwicki served as president and chief executive officer and a member of the board of directors of Civitas Therapeutics, Inc. from January 2014 until its acquisition by Acorda Therapeutics, Inc. in October 2014. From December 2012 to January 2014, Mr. Iwicki served as president and chief executive officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr. Iwicki was president and chief executive officer and director of Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc. Mr. Iwicki has an M.B.A. from Loyola University.

Len Kanavy
Member

Len Kanavy has been a member of the board since July 2018. Mr. Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech where he was responsible for strategic decisions of the US commercial business including product launches, valuation of business development opportunities, clinical development plan options and pricing. He was a member of the Commercial Leadership Committee and a Board Member of the Genentech Access to Care Foundation.

Prior to joining Genentech, Mr. Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business analytics, strategy, and product launches. He currently serves on the board of privately held KMK Consulting. Mr. Kanavy holds a B.S. in Business Administration and an MBA with a specialization in Finance from the University of Scranton.

John de Koning, Ph.D
Member

John de Koning, Ph.D. has been a member of the board since January 2010. Dr. de Koning has been a partner at Life Sciences Partners since January 2006. Dr. de Koning has served as a member of the board of directors of arGEN-X since September 2009 and currently serves on the boards of several private companies.

Previously, he served on the supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a non-executive director on the boards of Pronota (now MyCartis) and Innovative Biosensors Inc. Dr. de Koning has an M.Sc. in medical biology from Utrecht University and a Ph.D. in oncology from the Erasmus University Rotterdam.

Greg Perry, C.P.A.
Member

Gregory Perry has been a member of our board since May 2016. Mr. Perry has been the chief financial and administrative officer of Novelion Therapeutics, a biopharmaceutical company, since July 2015. Prior to joining Novelion Therapeutics, Mr. Perry served as chief financial and business officer of Eleven Biotherapeutics, Inc., a biopharmaceutical company, from December 2013 to July 2015, as interim chief financial officer of InVivo Therapeutics Holding Corp., a biotechnology company, from September 2013 to December 2013, and as chief financial officer of ImmunoGen, Inc., a biopharmaceutical company, from January 2009 to September 2013.

Mr. Perry currently serves as a director of a private biopharmaceutical company and previously served as a director of Ocata Therapeutics, Inc. from December 2011 to February 2016, when it was acquired by Astellas Pharma Inc. Mr. Perry holds a B.A. in economics and political science from Amherst College.

Anand Mehra, M.D.
Member

Anand Mehra, M.D. has been a member of the board since August 2015. Dr. Mehra has been with Sofinnova Ventures since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug development companies. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC.

He currently serves as a member of the boards of directors of Spark Therapeutics, Inc., Aerie Pharmaceuticals Inc., Aclaris Therapeutics, Inc. and Marinus Pharmaceuticals Inc. as well as the boards of several private companies. Dr. Mehra received his M.D. from Columbia University’s College of Physicians and Surgeons.

Anne Noordzij
Secretary

Scientific Advisory Board

Johannes Carolus Clevers, M.D., Ph.D

Antoni Ribas, M.D., Ph.D.

Ton Schumacher, Ph.D.

Josep Tabernero, M.D., Ph.D.

Johannes Carolus Clevers, M.D., Ph.D

Dr. Clevers is a Professor of Molecular Genetics at the University Medical Center Utrecht and Director of Research at the Princess Máxima Center for Pediatric Oncology. For ten years, Dr. Clevers served as the Director of the Hubrecht Institute of the Royal Netherlands Academy of Arts and Sciences and most recently served as President of the Royal Netherlands Academy of Science. His scientific research has focused on the biology of Wnt signaling in intestinal self-renewal and cancer.

Dr. Clevers discovered tissue stem cells in multiple organs through the Lgr5 stem cell marker. This led to establishment of organoid technology. He received his M.D., Ph.D., and M.Sc. in biology from the University of Utrecht with postdoctoral work completed at Dana-Farber Cancer Institute.

Antoni Ribas, M.D., Ph.D.

Dr. Ribas is a Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He also currently serves as Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Chair of the Melanoma Committee of the South West Oncology Group (SWOG) and a member of the Board of Directors of the American Association for Cancer Research (AACR).

Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. He trained at the University of Barcelona with postdoctoral research and clinical fellowships completed at UCLA.

Ton Schumacher, Ph.D.

Dr. Schumacher is a Senior Member at The Netherlands Cancer Institute, Professor of Immunotechnology at Leiden University Medical Center, Venture Partner at Third Rock Ventures and a scientific advisor to several emerging biotechnology companies. Dr. Schumacher is also the Founder of Neon Therapeutics and AIMM Therapeutics. He previously served as Chief Scientific Officer of Kite Pharma EU, which was formed following Kite Pharma’s acquisition of T Cell Factory, a company

Dr. Schumacher founded. Dr. Schumacher received his Ph.D. from The Netherlands Cancer Institute, a M.Sc. in medical biology from the University of Amsterdam and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.

Josep Tabernero, M.D., Ph.D.

Dr. Tabernero is the Director of the Vall d’Hebron Institute of Oncology (VHIO), Associate Professor in the Medicine Department at the Universitat Autònoma de Barcelona, and Director of Innovation, Care and Research at the Catalonian Oncology Network. Dr. Tabernero also holds several roles in the Medical Oncology Department at the Vall d’Hebron University Hospital, including Head of the Department, Clinical Director and Head of the Gastrointestinal Tumors Services and Phase 1 Unit.

Dr. Tabernero is a physician-scientist who conducts laboratory and clinical research in the field of gastrointestinal tumors with particular focus in early drug development. Dr. Tabernero received his M.D. and Ph.D. from the Universitat Autònoma de Barcelona.